期刊文献+

抗凝药物在早发型子痫前期中的应用 被引量:19

下载PDF
导出
摘要 目的通过给早发型子痫前期患者使用不同的抗凝治疗,探讨小剂量阿司匹林和低分子肝素的治疗效果。方法回顾性分析住院诊治的136例早发型子痫前期患者的妊娠结局,按照是否抗凝治疗分为3组:其中给予口服小剂量阿司匹林(50 mg/d)的35例设为观察组A,给予皮下注射低分子肝素(0.2~0.4 mL/d,连用7d)的30例设为观察组B,未给予抗凝治疗的71例设为对照组,对比这3组孕妇的妊娠结局。结果观察组A、观察组B和对照组子痫发生率分别为5.7%(2/35)、3.3%(1/30)和11.2%(8/71),新生儿低体重发生率分别为22.8%(8/35)、23.3%(7/30)和35.2%(25/71),新生儿窒息率分别为11.4%(4/35)、10.0%(3/30)和21.1%(15/71),产后出血率分别为5.7%(2/35)、3.3%(1/30)和5.6%(4/71)。观察组的子痫发病率、新生儿低体重、新生儿窒息均显著低于对照组(P<0.05),观察组A与观察组B差异无统计学意义(P>0.05)。结论抗凝治疗可以有效预防早发型子痫前期并发症的发生,低分子肝素和小剂量阿司匹林在抗凝治疗中都是安全有效的。
出处 《广东医学》 CAS CSCD 北大核心 2013年第8期1279-1280,共2页 Guangdong Medical Journal
  • 相关文献

参考文献7

  • 1丛克家.妊娠高血压综合征的诊断与治疗[M].北京:人民军医出版社,2002.300-302.
  • 2DEKKER J W, LIND J, BLOEMENKAMP K W, et al. Inherited risk of thrombosis of the fetus and intrauterine fetal death [ J ]. Eur J Obstet Gynecol Reprod Biol, 2004, 117( 1 ) : 45 -48.
  • 3林建华,张建平,贺晶,黄引平,余艳红.低分子肝素在产科中的应用[J].现代妇产科进展,2007,16(6):401-409. 被引量:64
  • 4叶柳青,汪丽萍,黄启涛,钟梅.低分子量肝素联合硫酸镁治疗早发型子痫前期的疗效观察[J].重庆医学,2012,41(9):864-866. 被引量:27
  • 5DULEY L, HENDERSON SMART D J, MEHER S, et al. Anti- platelet agents for preventing pre - eclampsia and its complications [J]. Cochrane Database Syst Rev, 2007, 18(2) : CD004659.
  • 6GRIS J C, CHAULEUR C, MOLINARI N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vas- cular complications in women with severe pre - eclampsia. The pi- lot randomised controlled NOH - PE trial [ J ]. Thromb Haemost, 2011, 106(6): 1053-1061.
  • 7URBAN G, VERGAN1 P, TIRONI R, et al. Antithrombotic prophylaxis in muhiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy [ J ]. Int J Fertil Womens Med, 2007, 52 (2/3) : 59 - 67.

二级参考文献15

  • 1于昕,林延峰.低分子量肝素对妊高征大鼠肾脏病变的保护作用及机制初步探讨[J].中国应用生理学杂志,2005,21(2):212-215. 被引量:13
  • 2曾菲,陈涤瑕,陶春莲,卢焕霞.妊娠期高血压疾病并发HELLP综合征终止妊娠时机及方式的探讨[J].实用妇产科杂志,2005,21(10):620-622. 被引量:17
  • 3Brenner B.Thrombophilia and pregnancy complications[J].Pathophysiol Haemost Thromb,2006,35(1/2):28-35.
  • 4D′ippolito S,Ortiz AS,Veglia M,et al.Low molecularweight heparin in obstetric care:a review of the literature[J].Reprod Sci,2011,18(7):602-613.
  • 5Middeldorp S.Low-molecular-weight heparin to preventpre-eclampsia:there is no evidence and potential harm[J].Neth J Med,2004,62(3):69-70.
  • 6Levey AS,Coresh J,Balk E,et al.National kidney founda-tion practice guidelines for chronic kidney disease:evalua-tion,classification,and stratification[J].Am J KidneyDis,2003,139(2):137-147.
  • 7Eslamian L,Behnam F,Tehrani ZF,et al.Random urineprotein creatinine ratio as a preadmission test in hyperten-sive pregnancies with urinary protein creatinine ratio[J].Acta Med Iran,2011,49(2):81-84.
  • 8Christopherson KW 2nd,Campbell JJ,Travers JB,et al.Low-molecular-weight heparins inhibit CCL21-induced Tcell adhesion and migration[J].J Pharmacol Exp Ther,2002,302(1):290-295.
  • 9Torricelli M,Reis FM,Florio P,et al.Low-molecular-weight heparin improves the performance of uterine ar-tery Doppler velocimetry to predict preeclampsia andsmall-for-gestational age infant in women with gestation-al hypertension[J].Ultrasound in Med&Bio,2006,32(9):1431-1435.
  • 10Kupferminc M,Rimon E,Many A,et al.Low molecularweight heparin versus no treatment in women with pre-vious severe pregnancy complications and placental find-ings without thrombophilia[J].Blood Coagul Fibrinoly-sis,2011,22(2):123-126.

共引文献99

同被引文献182

引证文献19

二级引证文献133

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部